Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A porcine model of neurofibromatosis type 1 that mimics the human disease.
White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM. White KA, et al. Among authors: dodd rd. JCI Insight. 2018 Jun 21;3(12):e120402. doi: 10.1172/jci.insight.120402. eCollection 2018 Jun 21. JCI Insight. 2018. PMID: 29925695 Free PMC article.
RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Samayoa AM, Major HJ, Cornick KE, Knepper-Adrian V, Khanna R, Sieren JC, Leidinger MR, Meyerholz DK, Zamba KD, Weimer JM, Dodd RD, Darbro BW, Tanas MR, Quelle DE. Kohlmeyer JL, et al. Among authors: dodd rd. Clin Cancer Res. 2020 Jun 15;26(12):2997-3011. doi: 10.1158/1078-0432.CCR-19-2706. Epub 2020 Feb 21. Clin Cancer Res. 2020. PMID: 32086342 Free PMC article.
Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
Kohlmeyer JL, Gordon DJ, Tanas MR, Dodd RD, Monga V, Darbro BW, Quelle DE. Kohlmeyer JL, et al. Among authors: dodd rd. Oncotarget. 2021 Jan 5;12(1):10-14. doi: 10.18632/oncotarget.27862. eCollection 2021 Jan 5. Oncotarget. 2021. PMID: 33456709 Free PMC article.
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
Kohlmeyer JL, Kaemmer CA, Lingo JJ, Voigt E, Leidinger MR, McGivney GR, Scherer A, Koppenhafer SL, Gordon DJ, Breheny P, Meyerholz DK, Tanas MR, Dodd RD, Quelle DE. Kohlmeyer JL, et al. Among authors: dodd rd. Neurooncol Adv. 2022 Apr 9;4(1):vdac047. doi: 10.1093/noajnl/vdac047. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35571990 Free PMC article.
PRC2 loss drives MPNST metastasis and matrix remodeling.
Brockman QR, Scherer A, McGivney GR, Gutierrez WR, Voigt AP, Isaacson AL, Laverty EA, Roughton G, Knepper-Adrian V, Darbro B, Tanas MR, Stipp CS, Dodd RD. Brockman QR, et al. Among authors: dodd rd. JCI Insight. 2022 Oct 24;7(20):e157502. doi: 10.1172/jci.insight.157502. JCI Insight. 2022. PMID: 36066973 Free PMC article.
Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism.
Gutierrez WR, Scherer A, Rytlewski JD, Laverty EA, Sheehan AP, McGivney GR, Brockman QR, Knepper-Adrian V, Roughton GA, Quelle DE, Gordon DJ, Monga V, Dodd RD. Gutierrez WR, et al. Among authors: dodd rd. JCI Insight. 2022 Nov 22;7(22):e159419. doi: 10.1172/jci.insight.159419. JCI Insight. 2022. PMID: 36227698 Free PMC article.
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Kohlmeyer JL, Lingo JJ, Kaemmer CA, Scherer A, Warrier A, Voigt E, Raygoza Garay JA, McGivney GR, Brockman QR, Tang A, Calizo A, Pollard K, Zhang X, Hirbe AC, Pratilas CA, Leidinger M, Breheny P, Chimenti MS, Sieren JC, Monga V, Tanas MR, Meyerholz DK, Darbro BW, Dodd RD, Quelle DE. Kohlmeyer JL, et al. Among authors: dodd rd. Clin Cancer Res. 2023 Sep 1;29(17):3484-3497. doi: 10.1158/1078-0432.CCR-23-0749. Clin Cancer Res. 2023. PMID: 37410426 Free PMC article.
44 results